Depending on the fat pad location, APs and adipocytes are heterogeneous. However, information on the pharmacological sensitivity of distinct APs to drugs known to alter the function of adipose tissue, especially HIV protease inhibitors (PIs) is scant. Here we show that PIs decreased proliferation and clonal expansion of APs, modifying their self-renewal potential. Lopinavir was the most potent PI tested. Decrease in self-renewal was accompanied by a reduced expression of the immediate early response gene IER3, a gene associated with tissue expansion. It was more pronounced in chin-derived APs than in knee-derived APs. Furthermore, lopinavir lowered the activin A-induced ERK1/2 phosphorylation. Expressions of the transcription factor EGR1 and its targets, including INHBA were subsequently altered. Therefore, activin A secretion was reduced leading to a dramatic impairment of APs self-renewal sustained by the activin A autocrine loop. All together, these observations highlight the activin A autocrine loop as a crucial effector to maintain APs self-renewal. Targeting this pathway by HIV-PIs may participate in the induction of unwanted side effects.
The adipose tissue (AT) represents the most adaptable tissue of an organism. It exists as functionally different depots that display opposite functions to fulfill the energy demand. In response to elevated calorie intake, white adipose tissue expansion allows energy storage as triglycerides. It represents the most abundant adipose tissue in adult humans. In contrast, brown adipose tissue is a key thermogenic organ able to produce heat from nutriments by uncoupling respiration from ATP synthesis. It surrounds the deepest organs 1 and represents the lesser part of adipose tissue. White AT is present all over the human body and is composed of distinct depots that are heterogeneous in terms of cellular composition, proliferation and differentiation 2, 3 .
The adipose progenitor (AP) pool hosted within the adipose tissues is crucial for AT development and to form new fat cells upon appropriated stimulus that induce adipocyte differentiation. This process is essential because like most mature and specialized healthy cells, adipocytes are generated through differentiation of progenitor cells as they do not divide in vivo. Thus, the AP pool is directly correlated with adipose tissue development and linked to fat mass 4 . Our lab has recently shown that the AP pools are derived from distinct embryonic origins. In rodents, while the intra-abdominal depots originate from mesoderm, those from the face display a neuro-ectodermal origin 5 . This feature is also encountered in humans since APs from chin and knee do not express the same homeobox genes (HOX) code. Indeed, they produce adipocytes displaying different phenotypes: upon adipose differentiation, chin APs give rise preferentially to cells with brown/brite adipocytes features while knee APs are prone to generate white adipocytes 6 . All these observations suggest that the different fat depots are not equal either in terms of structures but also for physiological and metabolic functions. As AP cells need to perpetuate all life long, this pool is located in niches that maintain their intrinsic properties and control the self-renewal throughout adult life. Many factors present in the adipose tissue microenvironment are involved in a proper regulation of the balance between self-renewal and differentiation of these cells, including activin A which maintains the AP pool through autocrine and paracrine mechanisms 7, 8 . In addition, we recently identified
Results
Differentiation of APs derived from different adipose depots in presence of PIs is not equivalent. Lopinavir but not darunavir, altered adipose progenitors differentiation. We measured the impact of DRV treatment on hMADS cells differentiation and compared it to LPV which is known to affect negatively the adipocyte maturation. We used concentrations in the range of those measured in the plasma of PI-treated patients. The therapeutic range for DRV was 10 µM onwards 23 and it was comprised between 2-12 mg/ml, i.e. 3.2-19 µM, for LPV 24 . Indeed treatment of hMADS cells incubated with the differentiation cocktail in presence of 20 µM DRV allowed the apparition of lipid droplets as shown by Oil Red O staining ( Fig. 1A and B) indicating that DRV is a weak inhibitor of adipose differentiation. In contrast differentiation was dramatically affected by a 10 µM LPV-treatment ( Fig. 1C) , indicating that the cells responded differently to these two drugs. Larger magnifications are presented in supplementary Fig. 1 . These results were further confirmed by analysis of adipose differentiation markers. After 17 days of differentiation in hMADS cells, we observed that DRV significantly decreased the expression of genes important for adipocyte differentiation in a dose dependent manner, such as the transcription factors C/EBPα and PPARγ (Fig. 1D-E ).In addition, LPV reduced the protein expression of the adipose marker FABP4 (Fig. 1F ). Note that LPV treatment led to stronger effect while using lower concentrations as compared to DRV.
APs from distinct fat depots displayed different sensitivity to LPV's effect. We determined the response of APs isolated from two distinct adipose depots from the same donor (chin and knee) 6 to the inhibitory effect of PIs on the differentiation process. Adipocyte differentiation in hMADS, knee or chin APs. After induction of differentiation for 17 days in absence or presence of PIs at the indicated concentrations, cells were fixed and further stained with Oil Red O. Differentiated cells displayed red staining within the lipid droplets. (D-E,J-K,P-Q) Expression of the adipogenic markers C/EBPα and PPARγ after 17 days of differentiation in absence or presence of increasing concentrations of PIs. Marker expression was assessed by real-time RT-PCR and normalized for the expression of 36B4 mRNA. Marker expression was measured in cells grown in the differentiation medium in absence of PIs (yellow bars) or in presence of DRV (green bars) or LPV (blue bars). The means ± SEM. were calculated from 3 (hMADS and knee) and 5 (chin) independent experiments, with determinations performed in duplicate (*p < 0.05, **p < 0.01, ***p < 0.001). (F,L,R) Expression of the adipogenic marker FABP4 after 17 days of differentiation in absence or presence of increasing concentrations of PIs. FABP4 expression was measured in cells grown in the differentiation medium in absence of PIs or in presence of increasing concentrations of DRV or LPV. Expression of Tubulin-βI used as a loading control (lower panel) and of FABP4 (upper panel) was analyzed by Western blot using specific antibodies. A typical autoradiograph is shown.
We noted that adipose differentiation occurred in all APs cells treated or not with 20 µM DRV as shown by oil Red O staining ( Fig. 1G ,H,M,N) while LPV impacted this mechanism in a larger extend without abolishing it ( Fig. 1I and O). In good correlation with our observations on hMADS cells, marker analysis revealed a dose-dependent impairment of differentiation when it was carried out in presence of DRV at concentrations higher than 20 µM in APs from knee ( Fig. 1J ). This result was further confirmed by protein analysis (Fig. 1l ). In contrast, no effect was observed on APs derived from chin even at 50 µM DRV and at 10 µM LPV, a concentration that was detrimental for hMADS cells and knee-APs differentiation ( Fig. 1D ,P and Q). Here again, LPV did not prevent expression of FABP4 in chin-APs ( Fig. 1R ). Note that C/EBPα expression was more sensitive to PIs treatment in chin and knee APs than PPARγ (Fig. 1J , K and P, Q), while these two genes were affected in a similar manner in hMADS cells ( Fig. 1D,E) .
All together these results indicated that depending on their origins, the different APs exhibit distinct sensitivities to the inhibitory effect of DRV or LPV on differentiation that may reflect the discrepancies observed in the antiretroviral-induced lipodystrophies.
Lopinavir but not darunavir, altered adipose progenitors proliferation. As a decrease in differentiation alone is not sufficient to explain the unwanted side effects of PIs observed in the face of patients treated with PIs, we analyzed the effects of PIs on APs self-renewal.
We first treated hMADS cells with LPV or DRV for 4 days (MTT assay) or 5 days (cell counts) to assess their impact on proliferation. While increasing doses of DRV did not cause a huge decrease in the cell number, LPV treatment significantly reduced proliferation by 25 to 75% for concentrations starting from 10 µM ( Fig. 2A and B ).
In addition LPV dramatically reduced their ability to grow at a single cell level while DRV did not display any effect. All together these results indicate that LPV, but not DRV, alters self-renewal of hMADS cells (Fig. 2C) .
These results prompted us to analyze self-renewal of APs isolated from different sites of the same donor upon PIs treatment. APs derived from chin were significantly impacted mainly by LPV while those derived from knee were less sensitive to PIs treatment ( Fig. 2D and E). These results were confirmed after measuring the effects of PIs on proliferation of chin and knee APs both coming from another distinct donor ( Supplementary Fig. 2 ).
We investigated the cytotoxic effects of PIs on APs, as we previously showed that low doses of LPV (1 µM) induced apoptosis in cancer stem cells expressing an embryonic signature 25 . After four days of culture in presence of LPV or DRV, cells were well attached to the tissue culture dish and more than 99.5% of cells were excluding trypan blue. We did not notice any induction of apoptosis by means of caspase 3 cleavage ( Supplementary Fig. 3 ) indicating that the impairment of APs proliferation induced by HIV-PI did not result from cytotoxic effects.
Signaling pathways altered by PIs. HIV-PIs' effect on IER3 mRNA expression. To gain mechanistic insights on PIs' effect, we analyzed IER3 expression in cells submitted to PIs treatment. In good correlation with the absence of inhibition of proliferation, a 5-day treatment with low doses of DRV did not impact significantly IER3 expression either in hMADS cells or in the different APs used ( Fig. 3A-C) . In contrast LPV, which altered dramatically self-renewal, reduced IER3 by 80% in hMADS cells and in chin APs ( Fig. 3A and B ). Knee APs were less sensitive as IER3 expression was only reduced by 40% ( Fig. 3C ).
We analyzed IER3 expression after a longer chronic treatment of APs with PIs, as short term outcomes are not always reflecting the changes occurring in life-long cures. Indeed this decrease in IER3 expression was still observed and was significant when a 35-day treatment was achieved in hMADS cells (Fig. 4A ).
This indicated that concomitantly with APs proliferation, LPV impaired IER3 mRNA expression. Its effects depended on the original location of the distinct APs.
ERK activation was blunted by LPV. We next examined the effects of PIs on signaling pathways important for cell proliferation in hMADS cells grown for 35-days in presence or absence of PIs. We measured the ERK1/2 phosphorylation in response to activin A which is essential to maintain APs (hMADS) self-renewal 7, 8 .
While DRV did not significantly affect ERK 1/2 phoshorylation in response to activin A, LPV dose-dependently blunted the phosphorylation of ERK1/2 observed in response to this factor ( Fig. 4B and C) . In presence of LPV, we measured a phosphorylation level that was not significantly different from the non-stimulated control level ( Fig. 4C ).
Neither DRV, nor LPV affected the activin A-induced SMAD2 phosphorylation indicating that this pathway leading to inhibition of differentiation through a decrease in CEBPβ-LAP expression is not targeted by PIs ( Supplementary Fig. 4 ).
HIV-PIs modified the immediate early gene EGR1 expression: consequences for INHBA gene expression.
To assess the consequences of the LPV-induced limitation in ERK1/2 phosphorylation on the ERK cascade, we measured EGR1 expression in cells that received or not PIs treatment. We observed that neither a 5-day, nor a 35-day treatment with different concentrations of DRV significantly modified EGR1 expression ( Fig. 5A-D) . In contrast, LPV strongly and significantly impaired EGR1 expression irrespective of the length of the treatment ( Fig. 5A-D) . Inhibition was already reaching the maximum value at 5 µM LPV in chin-APs. A significant decrease was also observed at the protein level after 35 days of treatment with a 20 µM LPV concentration ( Fig. 5E and F) .
In addition, from RNA interference experiments with siRNAs to IER3 that were previously validated 7 , we observed that EGR1 expression was dependent on IER3 expression ( Fig. 5G ), indicating that LPV may alter IER3 prior to EGR1.
We measured the expression of p53 which is directly controlled by EGR1 at the transcriptional level 26 and of its direct target p21. We found that the LPV-induced decrease in EGR1 expression after 35 days of treatment was accompanied by a significant reduction in the mRNA levels of both p53 and p21 ( Fig. 5H and I) . DRV which does not modify EGR1 expression did not affect either the expression of p53 or p21. This indicates that the decrease in EGR1 expression is followed by functional consequences on the gene expression pattern of LPV-treated cells. Although a decreased expression of p53 may favor cell growth, we did not observe such an event in LPV-treated cells.
In this regard, we focused on pathways important to sustain self-renewal in APs. In silico analysis revealed the presence of EGR1 binding elements in the INHBA promoter. We further measured the effect of LPV on INHBA expression. After 35 days of treatment with PIs, we observed that LPV decreased significantly INHBA expression in hMADS cells while DRV had no effect (Fig. 5J ).
This observation prompted us to quantify INHBA expression in cells treated with PIs for a shorter periodi. e. 5 days. We observed that a short term treatment with LPV was sufficient to reduce INHBA expression in hMADS cells and in chin AP ( Fig. 6A and B ). To confirm these observations, we measured activin A secretion in PI-treated cells. Indeed we noticed that a four-day treatment with LPV reduced activin A secretion ( Fig. 6C ). All together, our results indicated that LPV altered self-renewal by both decreasing the production of activin A and impairing its signaling pathway, hindering then the autocrine loop sustaining the AP pool. To ensure that EGR1 was involved in this regulation, INHBA expression was measured in cells overexpressing EGR1 after lentiviral transduction. Indeed, we observed that a 3-time increase in EGR1 expression led to an enhanced expression of INHBA ( Fig. 6D and E) indicating that expression of INHBA was dependent on the presence of EGR1.
The summary of the results and the pathway altered by HIV-PIs is presented in Fig. 7 . 
Discussion
APs isolated from different depots display distinct molecular signatures which have been related to their embryonic origin 5, 6 . In this paper we aimed to point out the heterogeneity of APs derived from human distinct fat depots by means of their respective sensitivities to pharmaceutical treatments. We focused on drugs known to affect adipose tissue homeostasis: the PIs which are part of HIV-ART therapy. Among its deleterious side effects, this treatment influences adipose tissues repartition. It promotes lipodystrophy development, leading then to a paucity of fat that impairs energy homeostasis. This represents a relevant approach to pinpoint the specific features (self-renewal and differentiation) of distinct APs and to identify the pathways playing a crucial role in their perpetuation. We used APs from different origins 6 in addition to abundantly described models of APs 17, 18 . Ten years ago, the inhibition of adipose differentiation induced by PIs and NRTI was reported in murine as well as human models 17 . A lack of differentiation was the only designed culprit responsible for lipodystrophies -even lipoatrophies-and this mechanism appeared as sufficient to explain the evolution of this unwanted side effect. In good agreement with these results, we found here that adipose differentiation of hMADS and APs from knee was drastically impacted by LPV treatment in a dose-dependent manner. However, the chin-derived APs were only impacted significantly when 20 µM LPV was used, thus pointing out important differences in sensitivity to LPV treatment among the distinct AP pools. This indicated that inhibition of differentiation may not be the major cause of lipoatrophy in the chin fat pad induced by HIV-ART. Indeed we found that proliferation of chin APs was dramatically reduced both by LPV and DRV, LPV being the most efficient molecule for doses as low as 5 µM significantly impaired cell growth. Note that these molecules did not display cytotoxic effects in APs while low doses of LPV induced apoptosis in cancer stem cells expressing an embryonic signature 25 , reflecting again huge differences in sensitivity between distinct cell types. In this regard, APs from different depots displayed proper sensitivities to DRV and LPV. We measured this effect in paired samples issued from different donors indicating that it was an unrestricted observation. Proliferation was also reduced in the other APs analyzed here, and this effect has to be considered in addition to the inhibition of differentiation, indicating that several processes may contribute all together to alteration of the fat pads expansion. Absence of differentiation efficiently reduces production of adipocytes when APs are present. In addition any reduction in the AP pool is susceptible to cause adipose tissue remodeling and to decrease fat depot development.
Our in vitro observations are in lane with clinical reports revealing that different manifestations of the HIV-ART were observed in AIDS patients. As an example, lipoatrophy of the face and neck adipose tissues can be observed concomitantly with hypertrophy of the visceral adipose tissue. These two antagonistic situations could even be observed in the same patient indicating that all adipose depots do not display identical responses to HIV-PI in vivo 16 . Of note, PIs were reported as lipoatrophy-inducers in the face 27 . Thus, any shrinkage of the AP pool may account for the irreversible HIV-ART-induced lipoatrophies that were observed.
We then aimed to decipher the molecular mechanisms altered by HIV-ART that underlie the adverse effects on APs self-renewal.
Several genes and signaling pathways control the balance between self-renewal and differentiation in stem cells. Recently, we focused on activin A and its crucial role to maintain self-renewal in adipose progenitors 7, 8 . We pointed out that activin A was involved in the preservation of AP pools by coordinating the balance between self-renewal and differentiation in an autocrine manner 7, 8 . Similarly, activin A also sustains self-renewal of human ES cells 28, 29 and its upregulation is required to maintain mesenchymal features of cancer stem-like cells in non-small cell lung cancer 30 indicating that its role is not restricted to APs.
The immediate early response gene IER3 is expressed in a wide range of tissues 31 and we recently showed that activin A controls its expression 7 . It has been reported to participate to several processes including cell survival, proliferation or apoptosis 9, 32 . Its pro-survival properties are relevant in a context of stem cells that need to perpetuate all life-long but also in a context of a tissue that needs to adapt to metabolic constraints [33] [34] [35] . Indeed, expression of IER3 was crucial to maintain and expand the adipose progenitor pool in response to effectors present in the microenvironment, including activin A 7 . Although, an elevation of IER3 expression was measured in the APs isolated from obese patients, information concerning its expression in lipodystrophic individuals is scant and difficult to reach due to ethical considerations. We noted that LPV treatment which altered self-renewal of APs lowered IER3 expression in these cells. This indicated that this gene is closely linked to the self-renewal status of the AP pools. Interestingly, not all the APs responded in a similar manner. We observed a consequent LPV-induced diminution in IER3 expression mainly in chin-derived APs, which is in lane with the LPV-induced alteration of proliferation measured in these cells.
as a loading control (lower panel) and of EGR1 (upper panel) is presented. All bands are issued from the same exposure of the blots. (F) Quantification of the signals. EGR1 expression was measured using the Quantity one Program and compared to the expression of Tubulin-βI. Four independent determinations were analyzed (***p < 0.001). ND means "no significant difference". (G) EGR1 expression was determined in hMADS cells transfected with non-relevant siRNA or with siRNA to decrease IER3 expression for 3 days. The analysis findings were assessed by real-time RT-PCR and normalized for the expression of 36B4 mRNA. Mean ± SEM. was representative of four independent experiments (p = 0.0107). (*p < 0.05). (H,I,J) Expression of EGR1 downstream genes. p53, p21 and INHBA expressions were determined in hMADS cells submitted or not to increasing doses of DRV (green bars) or LPV (blue bars) for 35 days. The analysis findings were assessed by real-time RT-PCR and normalized for the expression of 36B4 mRNA. Mean ± SEM. was representative of three independent experiments (ND = not significantly different, *p < 0.05, **p < 0.01, ***p < 0.001). From RNA interference experiments, we previously showed that IER3 supports activin A-induced self-renewal of APs through phosphorylation of ERK1/2 and activation of this regulatory network 7 . In good agreement, we observed that LPV, which reduces IER3 expression, significantly blunted the activin A-induced phosphorylation of ERK1/2 in APs. The alteration of this key pathway involved in cell proliferation may account for the negative impact of LPV on proliferation. In addition, these results and those previously reported 7 show that IER3 expression is correlated with the expandability of the adipose tissue and reflects its adaptation to metabolic constraints in physiopathological conditions.
To further identify the cascade leading to a decrease in proliferation, we concentrated on the multifunctional transcription factor EGR1 which is highly dependent on ERK1/2 phosphorylation in self-renewing stem cells 36, 37 . Furthermore, EGR1 has been identified as one of the positively regulated target genes by activin A in the murine gonadotrope-derived LBT2 cell line 38 . EGR1 is a DNA binding protein able to regulate the expression of a large number of genes, then controlling important cellular processes such as survival, cell growth, differentiation, senescence, transformation or apoptosis. In addition to the three zinc finger motifs and two nuclear localization signals, the structural analysis reveal the presence of a strong activation followed by a repression domain while a weak activation domain is located at the C terminus, indicating that EGR1 can function as a positive or negative regulator of transcription 39 . For instance, EGR1 promotes cell proliferation in some cancers cells 40, 41 and has also been associated with enhanced cell survival and tumor progression 20, 42 , while inhibition of EGR1 contributes to anti mitogenic effects in vascular smooth muscle cells 43 or cancer cells 44 . EGR1 was shown to play an essential role in many differentiation processes leading to the production of functional cell types including B cells, macrophages, neuroblastoma cells and adipocytes 45 . Its anti-adipogenic action is important to maintain appropriate levels of adipogenesis and/or a pool of resting APs able to undergo specialization upon appropriate stimulus in their microenvironment. In agreement with this finding, RNA interference experiments revealed that EGR1 expression was depending on IER3, an important target in the activin A self-renewal signaling pathway in our model. Our results indicated that LPV negatively targeted EGR1 expression as well as the expression of its downstream genes including INHBA, while EGR1 overexpression promoted INHBA expression. All together, these observations are in lane with a LPV-induced alteration of self-renewal of APs and they bring further evidences in the identification of the actors involved in the activin A autocrine loop that sustains APs self-renewal.
So far, the intracellular receptor or target for LPV remains unknown. Our results indicate that LPV, but not DRV, blunts the proliferation/self-renewal pathway activated by activin A. Note that LPV reduces also its production by lowering the transcription of INHBA gene and the secretion of activin A in APs. This contributes to turn down one of the autocrine loops critical to maintain the stemness properties of the AP pool. Note that any deterioration of this pathway is sufficient to dramatically alter self-renewal.
In conclusion, our work underlines the heterogeneity in the responses of distinct APs to HIV-PIs. While proliferation and self-renewal were preferentially impaired in APs derived from chin, differentiation was mostly impacted in APs derived from knee, indicating that all features of APs may account for lipodystrophy development. We identified a cascade of events that were important to sustain the self-renewal ability of APs. Cell autonomous regulation through activin A production appeared as an important, and somehow underestimated so far, pathway to perpetuate the AP pools. In this regard, the identification of IER3 and EGR1 as crucial genes to control self-renewal in physio-pathological conditions may give new insights to target and control the adipose tissue development and indeed for successful de novo adipogenesis in restoring facial defects. Figure 7 . : Summary of the results found. Activin A sustains self-renewal through activation of IER3 expression. LPV impairs IER3 expression that impacts ERK1/2 phosphorylation and EGR1 expression. EGR1 downstream pathway is then affected. This implies a decrease in Activin A production and an impairment of the activin A autocrine signaling that alters proliferation and clonal expansion of APs.
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Material and Methods
Reagents. Unless specified otherwise, all reagents were obtained from Sigma (Saint-Quentin Fallavier, France).
Tissue culture media were obtained from LONZA (Levallois-Perret, France) and foetal calf serum (FCS) from Dutscher S.A. (Brumath, France). Protease Inhibitors were obtained by extraction from commercially available tablets and capsules and purified by silica gel column chromatography. Their purity was assessed by 1 H and 13 C nuclear magnetic resonance and mass spectroscopy. Pure molecules were dissolved in DMSO. The key intermediates used for structure-activity relationship studies were synthesized according to a previously reported procedure 46 .
Cell culture. Human APs cells used for in vitro studies derived from distinct sources. hMADS cells 6 were isolated more than fifteen years ago from adipose tissue, as surgical scraps from surgical specimen of various surgeries of young donors, with the informed consent of the parents. All methods were approved and performed in accordance with the guidelines and regulations of the Centre Hospitalier Universitaire de Nice Review Board.
Chin and knee paired APs were derived from the stroma vascular fraction of Caucasians women who underwent elective liposuction procedures. Informed consent was obtained from all patients 44, 45 . APs were grown, maintained and differentiated according to experimental conditions previously described for each cell type 6, 45, 47 .
For proliferation experiments. cells were seeded at 3 000 cells/cm 2 . They were incubated in complete culture medium. The cells were counted using a Beckman Coulter Z1.
Proliferation based on MTT assay. Proliferation of human APs was evaluated using the soluble tetrazolium salt MTT reduction assay 48 . Briefly, cells were seeded at 1500 cells/well in quadruplicate in 96-well plates and incubated at 37 °C for the indicated time. MTT (0.5 mg/ml) was added to each well and cells were further incubated for 4 h. Then the insoluble formazan was dissolved in isopropanol and DMSO (v/v) and the OD was determined spectrophometrically at 562 nm and 630 nm for background correction.
A clonogenic assay. was carried out by plating 200 cells in a 100 mm-dia. dish in complete growth medium (containing 10% SVF) for 21 days. Colonies were scored after staining with crystal violet (1%). Each experiment was carried out in triplicate.
Adipocytic differentiation. was carried out as previously described and was assessed by Oil Red O staining 6, 47 .
Viral infection. Lentiviral particles were produced transfecting the 293 T cell line with the 2K7BSD-EGR1
constructs along with the packaging vectors. After lentiviral infection, cell lines stably expressing EGR1 were selected in appropriate blasticidin containing-medium (1 μg/mL) for at least 15 days. Two stable cell lines were developed from independent viral productions/infections and exhibited identical behaviors. Cells stably expressing the TOMATO-Fluorescent Protein (TOMATO) were obtained after 2K7BSD-Tomato lentiviral particles infection and were used as control.
Gene expression analysis. Total RNA was extracted using the TRI-Reagent kit (Euromedex, Soufflweyersheim, France) and reverse transcription (RT) was performed using MMLV reverse transcriptase (Promega, Charbonnieres, France), as recommended by the manufacturers. All primer sequences are described in supplementary section. Real-time PCR assays were run on an ABI Prism One step real-time PCR machine (Applied Biosystems, Courtaboeuf, France). Normalization was performed using 36B4 as a reference gene. Quantification was performed using the comparative Ct method.
Protein expression. Cells were rinsed in ice-cold PBS and whole cell extracts were prepared as described 7 .
Briefly, cells were lysed in the cell lysis buffer 49 , sonicated for 10 s and centrifuged at 12000 g for 10 min.
Thirty micro grams of proteins were resolved by SDS-PAGE under reducing conditions and transferred to Immobilon-P membranes (Millipore, Molshiem, France). The detection antibodies listed in supplementary section were used according to the manufacturer's instructions.
The bound primary antibody was detected by horseradish peroxidase-conjugated secondary antibody and visualized using an ECL detection kit (Millipore, Molsheim, France).
Chemiluminescence was observed using a molecular imager ChemiDoc XRS system (Bio-Rad, Marne la Coquette, France). The band intensity was quantified using Bio-Rad Quantity One software. Activin A secretion. Activin A secretion was assessed as previously described 8 . Briefly, hMADS cells were maintained in 5 µg/ml insulin and 10 µg/ml transferrin medium in the absence or presence of LPV or DRV as indicated. Culture media were collected 4 days later, filtered on 0.45 µm membranes, and concentrated with Amicon ultra-15 columns (NMWL, three KDa; Millipore). Levels of activin A were analyzed by Western blot performed under nonreducing conditions because anti-activin A antibody selectively binds to the dimeric form of activin A. Secreted enolase one (ENO1) was used as a loading control 50 .
Statistical analysis.
The results are shown as mean ± standard error of the mean (SEM), with the number of experiments indicated. Statistical significance was determined by t-tests using Micrococal Origin 6.0 (Micrococal Software, Northampton MA). Probability values <0.05 were considered statistically significant and are marked with a single asterisk, <0.01 with double asterisks and <0.001 with triple asterisks.
